Outpatient Epcoritamab Demonstrates Efficacy and Safety in R/R DLBCL

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Sep 3, 2025-

Outpatient Epcoritamab Demonstrates Efficacy and Safety in R/R DLBCL

Epcoritamab shows promise for outpatient treatment of relapsed DLBCL, enhancing patient access and quality of life while managing side effects effectively.

AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial

The ability to dose Epkinly in the outpatient setting could provide broader access to the drug, experts said.The post AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial appeared first on Clinical Trials Arena.

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - Life Sciences British Columbia

NORTH CHICAGO, Ill. – AbbVie shared updated Phase 2 EPCORE® NHL-6 trial results on epcoritamab monotherapy dosing and monitoring.